Innovita Biological Technology Co., Ltd. (SHA:688253)
China · Delayed Price · Currency is CNY 57.79
+0.12 (0.21%)
At close: Sep 23, 2026
SHA:688253 Revenue
Innovita Biological Technology had revenue of 31.92M CNY in the quarter ending June 30, 2026, a decrease of -54.05%. This brings the company's revenue in the last twelve months to 286.33M, down -39.94% year-over-year. In the year 2025, Innovita Biological Technology had annual revenue of 422.03M, down -32.08%.
Revenue (ttm)
286.33M
Revenue Growth
-39.94%
P/S Ratio
27.22
Revenue / Employee
604.07K
Employees
474
Market Cap
7.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 422.03M | -199.36M | -32.08% |
| Dec 31, 2024 | 621.39M | 143.37M | 29.99% |
| Dec 31, 2023 | 478.02M | 31.40M | 7.03% |
| Dec 31, 2022 | 446.62M | 119.71M | 36.62% |
| Dec 31, 2021 | 326.91M | -710.19M | -68.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.28B |
| Aurisco Pharmaceutical | 1.70B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.69B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Chengdu Kanghua Biological Products | 1.22B |
| Bio-Thera Solutions | 1.01B |
| Daan Gene | 746.91M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |